Latest Biotechnology News

Page 9 of 80
BPH Global has secured a $1 million strategic placement to accelerate growth of its Indonesian seaweed trading operations, backed by record sales and robust infrastructure. This capital injection aims to boost trading volumes and pave the way for higher-margin revenue streams.
Ada Torres
Ada Torres
5 Feb 2026
The US Congress has reauthorized the Rare Pediatric Disease Priority Review Voucher program through September 2029, a move that could significantly benefit Neuren Pharmaceuticals as it advances its rare disease drug candidates.
Ada Torres
Ada Torres
5 Feb 2026
Neuren Pharmaceuticals has received detailed feedback from the US FDA on its clinical development plans for NNZ-2591 targeting hypoxic ischemic encephalopathy and Pitt Hopkins syndrome, paving a clearer path forward despite some delays.
Ada Torres
Ada Torres
4 Feb 2026
PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.
Ada Torres
Ada Torres
4 Feb 2026
Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.
Victor Sage
Victor Sage
4 Feb 2026
Island Pharmaceuticals secures FDA confirmation on Galidesivir’s development under the Animal Rule, unlocking a streamlined two-stage approval process and significant commercial incentives.
Victor Sage
Victor Sage
4 Feb 2026
Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.
Ada Torres
Ada Torres
4 Feb 2026
OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.
Ada Torres
Ada Torres
3 Feb 2026
Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.
Ada Torres
Ada Torres
3 Feb 2026
Actinogen Medical has raised approximately $17 million through a share placement and purchase plan to fund the completion of its pivotal XanaMIA Alzheimer’s trial following encouraging interim results.
Ada Torres
Ada Torres
2 Feb 2026
PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.
Ada Torres
Ada Torres
2 Feb 2026
PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.
Ada Torres
Ada Torres
2 Feb 2026